Rani Therapeutics Holdings, Inc. Class A (RANI)

In October 2025, Rani Therapeutics announced a collaboration with Chugai Pharmaceutical Co. and a private placement, leading to a stock surge and extended cash runway. In November 2025, the company reported its Third Quarter financial results. In December 2025, Rani repaid all outstanding debt. In January 2026, Alireza Javadi was promoted to Chief Technical Officer. In March 2026, Jesper Høiland was appointed as Head of Strategy and the company reported its Fourth Quarter and Full Year 2025 financial results, with the stock rising despite missing EPS forecasts. In April 2026, Dr. Sara Kenkare-Mitra was appointed as Strategic Advisor. In May 2026, Rani announced preclinical data demonstrating successful oral delivery of semaglutide and bioequivalence of RT-114. In June 2025, Rani received a Nasdaq notice regarding non-compliance with the minimum bid price requirement.

Rani Therapeutics' products do not exhibit traditional demand seasonality due to its focus on research, development, and regulatory milestones rather than commercial product sales. Stock seasonality analysis pertains to stock price fluctuations rather than demand for pipeline products.

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on enabling oral administration of biologics and drugs as an alternative to injections. Their core technology is the RaniPill capsule, an oral delivery platform for drug substances like antibodies and proteins. The company's pipeline includes RT-102 for osteoporosis, RT-105 for psoriatic arthritis, RT-110 for hypoparathyroidism, RT-111 for inflammatory conditions, RT-114 for obesity (in collaboration with ProGen Co., Ltd.), and RT-116 for oral semaglutide.

Rani Therapeutics Holdings, Inc. is headquartered in San Jose, California, and operates in the United States with subsidiaries in California (Rani Therapeutics, LLC) and Delaware (Rani Management Services, Inc.).

Rani Therapeutics' brand reputation has been positively impacted by the collaboration agreement with Chugai Pharmaceutical Co. and the private placement, validating their oral biologics platform. Analysts have issued positive ratings, with a consensus rating of "Moderate Buy." Strategic advancements and improved liquidity also contribute to a favorable perception.

Rani Therapeutics Holdings, Inc. has a mixed ownership structure including institutional (30.19% to 36.22%), insider (28.64% to 33.04%), and retail investors (30.74% to 60.65%). Major institutional owners include Ra Capital Management, L.P., Samsara BioCapital, LLC, AWM Investment Company, Inc., SymBiosis Capital Partners, LLC, Vanguard Group Inc., Longaeva Partners L.P., and Siren, L.L.C. The largest individual shareholder is Mir A. Imran, owning 20.12% of the company.